Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum

被引：17

作者：

Ingels, Joline ^{[1
,2
]}

De Cock, Laurenz ^{[2
,3
]}

Stevens, Dieter ^{[2
,4
]}

Mayer, Rupert L. ^{[2
,3
,5
]}

Thery, Fabien ^{[3
,5
]}

Sanchez, Guillem Sanchez ^{[6
,7
,8
,9
]}

Vermijlen, David ^{[6
,7
,8
,9
]}

Weening, Karin ^{[1
]}

De Smet, Saskia ^{[10
]}

Lootens, Nele ^{[10
]}

Brusseel, Marieke ^{[10
]}

Verstraete, Tasja ^{[4
]}

Buyle, Jolien ^{[4
]}

Van Houtte, Eva ^{[10
]}

Devreker, Pam ^{[10
]}

Heyns, Kelly ^{[10
]}

De Munter, Stijn ^{[1
,2
]}

Van Lint, Sandra ^{[2
,4
]}

Goetgeluk, Glenn ^{[1
]}

Bonte, Sarah ^{[2
,5
]}

Billiet, Lore ^{[1
,2
]}

Pille, Melissa ^{[1
]}

Jansen, Hanne ^{[1
]}

Pascal, Eva ^{[1
,2
]}

Deseins, Lucas ^{[1
,2
]}

Vantomme, Lies ^{[3
]}

Verdonckt, Maarten ^{[1
]}

Roelandt, Ria ^{[11
,12
]}

Eekhout, Thomas ^{[11
,12
]}

Vandamme, Niels ^{[11
,12
]}

Leclercq, Georges ^{[1
]}

Taghon, Tom ^{[1
]}

Kerre, Tessa ^{[2
,5
,13
]}

Vanommeslaeghe, Floris ^{[14
]}

Dhondt, Annemieke ^{[14
]}

Ferdinande, Liesbeth ^{[2
,15
]}

Van Dorpe, Jo ^{[2
,15
]}

Desender, Liesbeth ^{[16
]}

De Ryck, Frederic ^{[16
]}

Vermassen, Frank ^{[16
]}

Surmont, Veerle ^{[4
]}

Impens, Francis ^{[3
,5
]}

Menten, Bjorn ^{[2
,3
]}

Vermaelen, Karim ^{[2
,4
]}

Vandekerckhove, Bart ^{[1
,2
,10
]}

机构：

[1] Univ Ghent, Dept Diagnost Sci, B-9000 Ghent, East Flanders, Belgium

[2] Canc Res Inst Ghent CRIG, B-9000 Ghent, East Flanders, Belgium

[3] Univ Ghent, Dept Biomol Med, East-Flanders, B-9000 Ghent, East Flanders, Belgium

[4] Ghent Univ Hosp, Resp Med, B-9000 Ghent, East Flanders, Belgium

[5] VIB UGent Ctr Med Biotechnol, VIB, East-Flanders, B-9052 Ghent, East Flanders, Belgium

[6] Univ Libre Bruxelles, Dept Pharmacotherapy & Pharmaceut, B-1050 Brussels, Belgium

[7] Univ Libre Bruxelles, Inst Med Immunol, B-1050 Brussels, Belgium

[8] Univ Libre Bruxelles, Ctr Res Immunol, B-1050 Brussels, Belgium

[9] WEL Res Inst, WELBIO Dept, B-1300 Wavre, Walloon Brabant, Belgium

[10] Ghent Univ Hosp, GMP Unit Cell Therapy, Ghent, East Flanders, Belgium

[11] VIB, VIB Single Cell Core, B-9000/ Ghent, East Flanders, Belgium

[12] VIB, VIB Single Cell Core, B-3000 Leuven, Flemish Brabant, Belgium

[13] Ghent Univ Hosp, Hematol, B-9000 Ghent, East Flanders, Belgium

[14] Univ Ghent, Ghent Univ Hosp, Nephrol, B-9000 Ghent, East Flanders, Belgium

[15] Ghent Univ Hosp, Pathol, B-9000 Ghent, East Flanders, Belgium

[16] Ghent Univ Hosp, Thorac & Vasc Surg, B-9000 Ghent, East Flanders, Belgium

来源：

CELL REPORTS MEDICINE | 2024年 / 5卷 / 05期

关键词：

PD-1; BLOCKADE; MEMORY; MUTATIONS; DIVERSITY; MELANOMA; ENABLES; HEALTH; IDENTIFICATION; IMMUNOTHERAPY; CHEMOTHERAPY;

D O I：

10.1016/j.xcrm.2024.101516

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Non-small cell lung cancer (NSCLC) is known for high relapse rates despite resection in early stages. present the results of a phase I clinical trial in which a dendritic cell (DC) vaccine targeting patient neoantigens is evaluated in patients with resected NSCLC. Vaccine manufacturing is feasible enrolled patients. Toxicity is limited to grade 1-2 adverse events. Systemic T cell responses in five out of six vaccinated patients, with T cell responses remaining detectable up to 19 months nation. Single-cell analysis indicates that the responsive T cell population is polyclonal and exhibits entire spectrum of T cell differentiation states, including a naive-like state, but excluding exhausted states. Three of six vaccinated patients experience disease recurrence during the follow-up period Collectively, these data support the feasibility, safety, and immunogenicity of this treatment NSCLC.

引用

页数：31

共 94 条

[11]

Bot A., 2018, PLOTKINS VACCINES, V161-184, P6, DOI [10.1016/B978-0-323-35761-6.00013-4, DOI 10.1016/B978-0-323-35761-6.00013-4]

[12] An accelerated, clinical-grade protocol to generate high yields of type 1-polarizing messenger RNA-loaded dendritic cells for cancer vaccination [J].